PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.36%
Cash & equivalents yoy growth below half of AGEN's 77.32%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
2.36%
Below half of AGEN's 77.32%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.66%
Other current assets growth < half of AGEN's 7.36%. David Dodd sees a leaner approach to short-term items.
1.99%
Below half of AGEN's 65.70%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.06%
≥ 1.5x AGEN's -1.96%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AGEN's -59.31%. David Dodd sees an aggressive push into LT investments. Confirm risk management.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.24%
≥ 1.5x AGEN's -1.93%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Below half of AGEN's 13.98%. Michael Burry sees a potential red flag for stagnation or capital shortage.
22.15%
Above 1.5x AGEN's 0.30%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AGEN's -30.77%. David Dodd sees stronger subscription/prepayment demand.
No Data
No Data available this quarter, please select a different quarter.
20.63%
Above 1.5x AGEN's 5.73%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Similar yoy changes to AGEN's 107.89%. Walter Schloss sees parallel tax deferral patterns.
No Data
No Data available this quarter, please select a different quarter.
-0.37%
Less than half of AGEN's 27.09%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
3.44%
Less than half of AGEN's 14.85%. David Dodd sees far fewer liability expansions relative to competitor.
6.90%
Above 1.5x AGEN's 0.48%. Michael Burry suspects heavy new equity expansion or dilution.
-3.28%
1.25-1.5x AGEN's -2.63%. Bruce Berkowitz notes stronger reinvestment strategy.
100.00%
Above 1.5x AGEN's 6.54%. Michael Burry sees a significant jump in intangible or market-based gains. Scrutinize risk of reversal.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AGEN's zero value, indicating worse performance.
-0.05%
Below half AGEN's -19.80%. Michael Burry sees potential underperformance in building shareholder capital.
1.71%
Below half AGEN's 13.98%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.63%
Below half AGEN's -0.95%. Michael Burry suspects major underinvestment or forced divestment.
-6.71%
Less than half of AGEN's -76.74%. David Dodd sees less overall debt expansion vs. competitor.
-2.57%
Less than half of AGEN's -104.36%. David Dodd sees better deleveraging or stronger cash buildup than competitor.